Open letter to AbbVie to make glecaprevir/pibrentasvir (G/P) accessible for people with hepatitis C

MSF Access Campaign sent an open letter to pharmaceutical corporation AbbVie, urging them to make the medicine glecaprevir/pibrentasvir (G/P) more accessible to treat people with hepatitis C in low- and middle-income countries (LMICs), including in MSF programmes.

Since 2018, MSF has made numerous requests to AbbVie to enable the procurement of G/P. But this lifesaving treatment continues to remain out of reach for many people with hepatitis C in LMICs.

MSF calls on AbbVie to:

1. Establish a compassionate use program for people for whom other regimens have failed, in all LMICs where G/P remains unregistered and unavailable. 
2. Expedite registration of G/P in LMICs. 
3. Offer G/P at an affordable price for people in MSF’s programmes in Pakistan and people in LMICs. 
4. Expand the territory of the G/P voluntary licensing agreement with the Medicines Patent Pool (MPP) to ensure generic companies have sufficient incentive to develop and supply this essential treatment.